<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034940</url>
  </required_header>
  <id_info>
    <org_study_id>OxiSTEMI01</org_study_id>
    <nct_id>NCT04034940</nct_id>
  </id_info>
  <brief_title>Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI</brief_title>
  <acronym>OxiSTEMIhFABP</acronym>
  <official_title>Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grigore T. Popa University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiovascular Diseases Institute IASI, Romania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grigore T. Popa University of Medicine and Pharmacy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to evaluate Oxidative Stress biomarkers through a. Catalase Activity
      Assay; b. Lipid Peroxidation Assay; c. SOD Assay; d. Total Antioxidant Capacity Assay; e.
      Glutathione Peroxidase at patients with acute myocardial infarction STEMI referred for
      primary PCI; The investigators also aim to evaluate cardiac necrosis by measuring Heart Fatty
      Acid Binding Protein (H-FABP), TnI, CK, CK-MB, LDH and AST in these patients with acute
      myocardial infarction referred for primary PCI; Also, the investigators intend to evaluate
      body composition through bioimpedance spectroscopy (BCM - Fresenius Care) at the moment of
      admission.

      The investigators aim to fully characterise these patients through oxidative millieu, hFABP
      and make correlations with LVEF dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gathered data:

        -  Descriptive general demographic data;

        -  Previous pathologies (ischemic heart disease, peripheral arterial disease, stroke, heart
           failure, previous percutaneous coronary interventions, coronary artery bypass grafting -
           CABG, known renal disease);

        -  Cardiovascular risk factors (age, weight, height, abdominal perimeter, body mass index,
           smoking, sedentariness, diabetes, hypertension, dyslipidaemia);

        -  Oxidative Stress biomarkers: Catalase Activity Assay; Lipid Peroxidation Assay; SOD
           Assay; Total Antioxidant Capacity Assay; Glutathione ;

        -  Cardiac necrosis markers: Heart Fatty Acid Binding Protein (H-FABP), TnI, CK, CK-MB, LDH
           and OGT;

        -  Routine biological data;

        -  Metabolic data (obtained from two body composition monitoring evaluations - before and
           12 hours after coronary intervention) - body water, body fat tissue;

        -  Information regarding primary PCI (less than 12 hours of ischemic symptoms);

        -  Coronarographic details, type of used stent, periprocedural specific complications,
           final TIMI - thrombolysis in myocardial infarction - flow);

        -  Echocardiography at admission (LVEF);

        -  Measurement of arterial stiffness through Sphigmocore pulsed-wave-velocity (24 hrs
           post-procedural, 2 velocities: carotid - femoral and carotid - radial);

        -  Calculating of cardiovascular risk scores: Syntax Score, Framingham score, ASSIGN score,
           QRISK2 score, PROCAM score, CRUSADE score, GRACE score, CHADS VASc score, MESA score,
           ASCVD score, Hamilton Depression Rating Scale (HAM-D), Hamilton Rating Scale for
           Anxiety;

        -  In-hospital and one month follow-up MACE.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative Stress status in Acute Myocardial Infarction Patients undergoing primary PCI</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of oxidative stress status by measuring Catalase Activity Assay; Lipid Peroxidation Assay; SOD Assay; Total Antioxidant Capacity Assay; Glutathione Peroxidase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Cardiac necrosis status in Acute Myocardial Infarction Patients undergoing primary PCI.</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of cardiac necrosis by measuring Heart Fatty Acid Binding Protein (H-FABP), TnI, CK, CK-MB, LDH and AST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hydation Status in Acute Myocardial Infarction Patients undergoing primary PCI.</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of hydration status through body composition monitoring BCM.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>STEMI</condition>
  <condition>Oxidative Stress</condition>
  <condition>Oxidative Stress Induction</condition>
  <condition>Primary PCI</condition>
  <condition>hFABP</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <condition>BCM</condition>
  <arm_group>
    <arm_group_label>primary PCI STEMI patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All Patients with AMI refered for primary PCI in single center</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dosing Oxidative stress biomarkers &amp; hFABP in STEMI pPCI patients</intervention_name>
    <description>Dosing oxidative stress biomarkers and hFABP in STEMI pPCI</description>
    <arm_group_label>primary PCI STEMI patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with ST elevation Myocardial Infarction (&lt;12h) diagnostic confirmed;

          -  Included in the Romanian National Programme of Primary Percutaneous Revascularisation
             (for who the Guidelines recommend primary PCI);

        Exclusion Criteria:

          -  Patients who do not sign informed consent for primary PCI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Covic, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine and Pharmacy &quot;Gr. T. Popa&quot; Iasi, Romania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Razan Al Namat, MD, PhD stud</last_name>
    <phone>0040757205114</phone>
    <email>dr.razan_romania@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Diseases Institute Iasi</name>
      <address>
        <city>Ia≈üi</city>
        <state>Iasi</state>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandru Burlacu, MD, PhD</last_name>
      <phone>0040744488580</phone>
      <email>alburlacu@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 27, 2019</last_update_submitted>
  <last_update_submitted_qc>July 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Grigore T. Popa University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Professor Adrian Covic</investigator_full_name>
    <investigator_title>Professor, Vice-rector</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

